MX2016006633A - Uso de hidroxamatos de indolilo e indolinilo para tratar trastornos neurodegenerativos o deficiencias cognitivas. - Google Patents

Uso de hidroxamatos de indolilo e indolinilo para tratar trastornos neurodegenerativos o deficiencias cognitivas.

Info

Publication number
MX2016006633A
MX2016006633A MX2016006633A MX2016006633A MX2016006633A MX 2016006633 A MX2016006633 A MX 2016006633A MX 2016006633 A MX2016006633 A MX 2016006633A MX 2016006633 A MX2016006633 A MX 2016006633A MX 2016006633 A MX2016006633 A MX 2016006633A
Authority
MX
Mexico
Prior art keywords
indolyl
hydroxamates
idolinyl
neurodegenerative disorders
cognitive deficits
Prior art date
Application number
MX2016006633A
Other languages
English (en)
Inventor
Sheng Hung Kuo
Original Assignee
Univ Taipei Medical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Taipei Medical filed Critical Univ Taipei Medical
Publication of MX2016006633A publication Critical patent/MX2016006633A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/04—Nitro compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A61K31/37—Coumarins, e.g. psoralen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Psychology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se refiere al uso novedoso de hidroxamatos de indolilo e indolinilo. En particular, la invención se refiere al uso de hidroxamatos de indolilo e indolinilo en la elaboración de un medicamento o una composición farmacéutica para tratar una apoplejía isquémica y hemorrágica, lesión en médula espinal, lesión en nervio craneal, lesión en nervio periférico y algún trastorno neurodegenerativo o deficiencia cognitiva.
MX2016006633A 2013-11-24 2014-11-24 Uso de hidroxamatos de indolilo e indolinilo para tratar trastornos neurodegenerativos o deficiencias cognitivas. MX2016006633A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361908168P 2013-11-24 2013-11-24
PCT/US2014/067040 WO2015077685A1 (en) 2013-11-24 2014-11-24 Use of indolyl and idolinyl hydroxamates for treating neurodegenerative disorders or cognitive deficits

Publications (1)

Publication Number Publication Date
MX2016006633A true MX2016006633A (es) 2016-12-02

Family

ID=53180246

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016006633A MX2016006633A (es) 2013-11-24 2014-11-24 Uso de hidroxamatos de indolilo e indolinilo para tratar trastornos neurodegenerativos o deficiencias cognitivas.

Country Status (11)

Country Link
US (1) US9956202B2 (es)
EP (1) EP3096753A4 (es)
JP (1) JP2016537375A (es)
KR (1) KR20160079899A (es)
CN (1) CN106456606A (es)
AU (1) AU2014352716A1 (es)
CA (1) CA2931345A1 (es)
MX (1) MX2016006633A (es)
RU (1) RU2016125313A (es)
TW (1) TWI659017B (es)
WO (1) WO2015077685A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20240306T1 (hr) 2015-10-27 2024-05-10 Taipei Medical University Derivati indolina za liječenje i/ili prevenciju fibroznih bolesti
CN112135834A (zh) 2018-06-27 2020-12-25 雅玛山酱油株式会社 3’,3’-cGAMP的水合物晶体
WO2023076150A1 (en) * 2021-10-29 2023-05-04 Psilera Inc. Modified indole compounds

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9820113D0 (en) * 1998-09-15 1998-11-11 Merck Sharp & Dohme Therapeutic agents
CA2745073A1 (en) * 2008-12-03 2010-06-10 Li-Huei Tsai Inhibition of hdac2 to promote memory
TWI429628B (zh) * 2010-03-29 2014-03-11 Univ Taipei Medical 吲哚基或吲哚啉基羥肟酸化合物
CA2848877A1 (en) * 2011-09-15 2013-03-21 Taipei Medical University Use of indolyl and indolinvl hvdroxamates for treating heart failure or neuronal injury
CA2850707C (en) 2011-10-03 2023-03-21 The University Of Utah Research Foundation Application of 5-ht6 receptor antagonists for the alleviation of cognitive deficits of down syndrome
WO2013150529A2 (en) 2012-04-02 2013-10-10 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd Indole, indoline derivatives, compositions comprising them and uses thereof

Also Published As

Publication number Publication date
KR20160079899A (ko) 2016-07-06
US20160303079A1 (en) 2016-10-20
CA2931345A1 (en) 2015-05-28
JP2016537375A (ja) 2016-12-01
EP3096753A1 (en) 2016-11-30
AU2014352716A1 (en) 2016-06-09
TW201609640A (zh) 2016-03-16
WO2015077685A1 (en) 2015-05-28
RU2016125313A (ru) 2017-12-28
TWI659017B (zh) 2019-05-11
US9956202B2 (en) 2018-05-01
CN106456606A (zh) 2017-02-22
EP3096753A4 (en) 2017-07-05

Similar Documents

Publication Publication Date Title
HK1254665A1 (zh) 預防、改善或治療退行性腦病或認知功能障礙的新型乳酸菌和組合物
MX2017005834A (es) Polinucleotidos aad para el tratamiento de la enfermedad de parkinson.
MX2017002271A (es) Composiciones y metodos para el tratamiento de trastornos neurologicos.
MX365835B (es) Uso de akkermansia para tratar trastornos metabolicos.
PH12016502015A1 (en) Anti-factor d antibody variants and uses thereof
CL2014002334A1 (es) Compuestos derivados de indanos espirofusionados, inhibidores de la beta-secretasa; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como deterioro cognitivo, trastornos neurodegenerativos, demencia, entre otras.
PH12016501724A1 (en) Isoindolinone compounds as gpr119 modulators for the treatment of diabetes, obesity, dyslipidemia and related disorders
BR112015001959A2 (pt) composto, composição farmacêutica, métodos para melhorar os déficits cognitivos, para prevenir ou tratar déficits cognitivos distúrbios neurodegenerativos ou neuropsiquiátricos, para o tratamento ou prevenção de doenças inflamatórias e de dor neuropática, uso de um composto, e, processo para preparar um composto
MX370113B (es) Moduladores alostericos positivos del receptor muscarinico m2.
IL248118A0 (en) Converted inanone compounds as gpr119 regulators for the treatment of diabetes, obesity, dyslipidemia and related diseases
HK1205467A1 (en) Pharmaceutical composition for the prophylaxis and treatment of psychological, behavioral and cognitive disorders
ZA201802448B (en) Co-therapy comprising canagliflozin and phentermine for the treatment of obesity and obesity related disorders
EA201691567A1 (ru) Способы лечения легких травм головного мозга
PH12016501173A1 (en) Quinazolin-thf-amines as pde1 inhibitors
MX2016006633A (es) Uso de hidroxamatos de indolilo e indolinilo para tratar trastornos neurodegenerativos o deficiencias cognitivas.
HK1206720A1 (en) Pyrazole carboxamide derivatives as taar modulators for use in the treatment of several disorders, such as depression, diabetes and parkinsons disease taar
EP3052137A4 (en) Methods for the identification, assessment, prevention, and treatment of neurological disorders and diseases using fndc5
MX2015005733A (es) Compuestos triciclicos para usarse en el tratamiento y/o control de obesidad.
EP3357494A4 (en) THERAPEUTIC AGENT AND / OR PROPHYLACTIC AGENT FOR PERIPHERAL NERVE DISORDER OR SPINAL INJURY
CL2012002285A1 (es) Forma cristalina del 4-{(1s,2s)-2-[((r)-4-ciclobutil-2-metilpiperazin-1-il)carbonil]cicclopropil]benzamida; composicion farmaceutica, y su uso para el tratar esquizofrenia, narcolepsia, somnolencia diurna excesiva, obesidad, trastorno cognitivo asociado con esquizonfrenia.
MX2015008171A (es) Formulacion que comprende agomelatina amorfa.
GB201115977D0 (en) Neurodevelopmental disorders
MX2018007458A (es) Composiciones de benzofenonas polihidroxiladas y metodos para el tratamiento de trastornos neurodegenerativos.
EP2938198A4 (en) RECOMBINANT COLLAGEN 7 ADMINISTRATION FOR THE TREATMENT OF AGE-RELATED DISORDERS
GB201320506D0 (en) Cyclic amino compounds for the use in the treatment of cardiac disorders